99.06
price up icon1.21%   1.185
 
loading
Gilead Sciences Inc stock is traded at $99.06, with a volume of 4.78M. It is up +1.21% in the last 24 hours and down -6.12% over the past month. Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$97.88
Open:
$97.87
24h Volume:
4.78M
Relative Volume:
0.54
Market Cap:
$129.74B
Revenue:
$28.73B
Net Income/Loss:
$5.97B
P/E Ratio:
20.86
EPS:
4.75
Net Cash Flow:
$10.37B
1W Performance:
-7.02%
1M Performance:
-6.12%
6M Performance:
+1.19%
1Y Performance:
+51.33%
1-Day Range:
Value
$97.33
$99.70
1-Week Range:
Value
$97.33
$105.86
52-Week Range:
Value
$62.07
$119.96

Gilead Sciences Inc Stock (GILD) Company Profile

Name
Name
Gilead Sciences Inc
Name
Phone
(650) 574-3000
Name
Address
333 LAKESIDE DR, FOSTER CITY, CA
Name
Employee
17,600
Name
Twitter
@GileadSciences
Name
Next Earnings Date
2025-02-11
Name
Latest SEC Filings
Name
GILD's Discussions on Twitter

Compare GILD with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
GILD
Gilead Sciences Inc
99.03 129.74B 28.73B 5.97B 10.37B 4.75
Drug Manufacturers - General icon
LLY
Lilly Eli Co
773.87 696.19B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
157.05 370.90B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
ABBV
Abbvie Inc
188.13 342.31B 57.37B 4.20B 17.83B 2.35
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
67.22 289.25B 42.09B 14.65B 10.11B 3.2833
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
111.57 224.07B 53.22B 12.86B 14.85B 6.39

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-22-25 Resumed Cantor Fitzgerald Overweight
Mar-04-25 Reiterated Oppenheimer Outperform
Feb-18-25 Upgrade Deutsche Bank Hold → Buy
Feb-13-25 Upgrade DZ Bank Hold → Buy
Jan-10-25 Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-10-24 Resumed BofA Securities Buy
Nov-15-24 Initiated Wolfe Research Outperform
Nov-14-24 Initiated Citigroup Buy
Nov-08-24 Downgrade Maxim Group Buy → Hold
Oct-21-24 Upgrade Leerink Partners Market Perform → Outperform
Oct-17-24 Initiated Bernstein Outperform
Oct-07-24 Upgrade Wells Fargo Equal Weight → Overweight
Jul-08-24 Upgrade Raymond James Mkt Perform → Outperform
May-01-24 Reiterated Maxim Group Buy
Apr-24-24 Upgrade HSBC Securities Reduce → Hold
Feb-22-24 Downgrade Truist Buy → Hold
Nov-09-23 Initiated Deutsche Bank Hold
Sep-08-23 Upgrade BofA Securities Neutral → Buy
Sep-06-23 Initiated HSBC Securities Reduce
Jul-24-23 Reiterated Barclays Equal Weight
May-16-23 Upgrade BMO Capital Markets Market Perform → Outperform
Apr-28-23 Resumed Piper Sandler Overweight
Jan-03-23 Downgrade RBC Capital Mkts Outperform → Sector Perform
Dec-13-22 Resumed BofA Securities Neutral
Dec-09-22 Downgrade DZ Bank Buy → Hold
Oct-31-22 Upgrade Barclays Underweight → Equal Weight
Oct-28-22 Reiterated BMO Capital Markets Market Perform
Oct-28-22 Reiterated Cowen Outperform
Oct-28-22 Reiterated JP Morgan Overweight
Oct-28-22 Reiterated Jefferies Buy
Oct-28-22 Upgrade Piper Sandler Neutral → Overweight
Oct-28-22 Reiterated RBC Capital Mkts Outperform
Oct-28-22 Upgrade Truist Hold → Buy
Oct-28-22 Reiterated Wells Fargo Equal Weight
Oct-04-22 Upgrade JP Morgan Neutral → Overweight
Jul-13-22 Initiated Cantor Fitzgerald Neutral
May-23-22 Initiated SVB Leerink Mkt Perform
Feb-28-22 Downgrade BMO Capital Markets Outperform → Market Perform
Feb-02-22 Reiterated BMO Capital Markets Outperform
Feb-02-22 Reiterated BofA Securities Neutral
Feb-02-22 Reiterated RBC Capital Mkts Outperform
Feb-02-22 Reiterated Truist Hold
Feb-02-22 Reiterated Wells Fargo Equal Weight
Jan-28-22 Upgrade Argus Hold → Buy
Jan-06-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-09-21 Resumed Wells Fargo Equal Weight
Dec-06-21 Initiated Goldman Neutral
Nov-19-21 Upgrade BMO Capital Markets Market Perform → Outperform
Nov-19-21 Resumed Piper Sandler Neutral
Oct-20-21 Resumed Cowen Outperform
Jul-30-21 Reiterated BMO Capital Markets Market Perform
Jul-30-21 Reiterated RBC Capital Mkts Outperform
Apr-01-21 Upgrade Bernstein Mkt Perform → Outperform
Mar-30-21 Upgrade Redburn Neutral → Buy
Jan-19-21 Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-04-21 Upgrade Guggenheim Neutral → Buy
Nov-03-20 Resumed Morgan Stanley Equal-Weight
Oct-28-20 Initiated UBS Neutral
Sep-30-20 Resumed Jefferies Buy
Sep-15-20 Upgrade Maxim Group Hold → Buy
Jul-31-20 Reiterated Credit Suisse Neutral
Jul-31-20 Reiterated Morgan Stanley Equal-Weight
Jul-31-20 Reiterated Piper Sandler Overweight
Jul-31-20 Reiterated RBC Capital Mkts Outperform
Jul-31-20 Reiterated SunTrust Hold
Jul-31-20 Reiterated Wells Fargo Equal Weight
Jul-20-20 Upgrade Credit Suisse Underperform → Neutral
Jun-03-20 Upgrade SVB Leerink Mkt Perform → Outperform
May-26-20 Upgrade SunTrust Sell → Hold
May-01-20 Downgrade JP Morgan Overweight → Neutral
May-01-20 Downgrade Raymond James Outperform → Mkt Perform
May-01-20 Downgrade SunTrust Hold → Sell
Apr-27-20 Downgrade UBS Buy → Neutral
Apr-20-20 Downgrade BMO Capital Markets Outperform → Market Perform
Apr-20-20 Downgrade Wells Fargo Overweight → Equal Weight
Apr-17-20 Downgrade CFRA Hold → Sell
View All

Gilead Sciences Inc Stock (GILD) Latest News

pulisher
09:41 AM

Fighting the World’s Most Devastating Diseases Is the Focus of This Installment of “The Centrifuge Sessions - CSRwire

09:41 AM
pulisher
05:55 AM

Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025 - BioSpace

05:55 AM
pulisher
05:46 AM

Gilead (GILD): Livdelzi Shows Promising Results for PBC Treatment | GILD Stock News - GuruFocus

05:46 AM
pulisher
05:45 AM

GILD: Promising Results from Gilead's Bulevirtide Study for Chronic Hepatitis Delta | GILD Stock News - GuruFocus

05:45 AM
pulisher
02:41 AM

Gilead's Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy - GuruFocus

02:41 AM
pulisher
02:30 AM

Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment - Business Wire

02:30 AM
pulisher
May 06, 2025

Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

May 06, 2025
pulisher
May 06, 2025

Gilead (GILD) Sees Bearish Options Activity with Heavy Put Trading | GILD Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Fighting the World's Most Devastating Diseases Is the Focus of This Installment of "The Centrifuge Sessions" - marketscreener.com

May 06, 2025
pulisher
May 06, 2025

Gilead: Sure, Why Not, But Not The CDRs (GILD:CA) - Seeking Alpha

May 06, 2025
pulisher
May 05, 2025

What Are Wall Street Analysts' Target Price for Gilead Sciences Stock? - Nasdaq

May 05, 2025
pulisher
May 05, 2025

Mizuho Adjusts Price Target on Gilead Sciences to $117 From $100, Maintains Outperform Rating - marketscreener.com

May 05, 2025
pulisher
May 05, 2025

Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term - Yahoo

May 05, 2025
pulisher
May 05, 2025

What Are Wall Street Analysts' Target Price For Gilead Sciences Stock? - Barchart.com

May 05, 2025
pulisher
May 03, 2025

Gilead (GILD) Sees 24% Stock Surge Amid Tariff Resilience - GuruFocus

May 03, 2025
pulisher
May 03, 2025

Gilead and Vertex Pharma named among biotech’s tariff safe havens - MSN

May 03, 2025
pulisher
May 02, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

May 02, 2025
pulisher
May 02, 2025

Here's What to Expect From Gilead Sciences’ Next Earnings Report - MSN

May 02, 2025
pulisher
May 01, 2025

Struggling Peninsula biotech with Gilead lineage is latest purchase for activist investor - The Business Journals

May 01, 2025
pulisher
May 01, 2025

Gilead Sciences (GILD): A Promising Pick Amid Economic Uncertain - GuruFocus

May 01, 2025
pulisher
May 01, 2025

June 13th Options Now Available For Gilead Sciences (GILD) - Nasdaq

May 01, 2025
pulisher
May 01, 2025

Gilead Agrees To Pay $202M To Settle Alleged Speaker Kickback Claims In FCA Suit - Law360

May 01, 2025
pulisher
May 01, 2025

Gilead Sciences reaches $202 million settlement with US over kickbacks to doctors - MSN

May 01, 2025
pulisher
May 01, 2025

Gilead Sciences' (NASDAQ:GILD) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

Gilead Sciences Stock Falls as Slumping COVID-19, Cancer Drug Sales Hit Revenue - MSN

May 01, 2025
pulisher
Apr 30, 2025

BlackRock, Inc. Reduces Stake in Gilead Sciences Inc. - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Gilead Sciences: Hold Rating Maintained Amid Near-Term Challenges and Limited Growth Prospects - TipRanks

Apr 30, 2025
pulisher
Apr 30, 2025

Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now? - Yahoo Finance

Apr 30, 2025
pulisher
Apr 29, 2025

Gilead Will Pay $202M In DOJ Deal Over Drug Kickbacks - Law360

Apr 29, 2025
pulisher
Apr 29, 2025

Gilead Sciences to pay $202 million in US settlement over HIV drug kickbacks - Reuters

Apr 29, 2025
pulisher
Apr 29, 2025

Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis - BioSpace

Apr 29, 2025
pulisher
Apr 29, 2025

Gilead Sciences to Present at Upcoming Investor Conferences - BioSpace

Apr 29, 2025
pulisher
Apr 29, 2025

Gilead enters $202M settlement to resolve US government's long-running HIV kickbacks probe - Fierce Pharma

Apr 29, 2025
pulisher
Apr 29, 2025

Gilead will pay $202 million to settle charges of paying kickbacks to docs for boosting HIV drug sales - statnews.com

Apr 29, 2025
pulisher
Apr 29, 2025

Sector Update: Health Care Stocks Gain Late Afternoon - marketscreener.com

Apr 29, 2025
pulisher
Apr 29, 2025

Gilead Sciences Coughs Up $202 Million in Kickback Scandal Settlement Over HIV Drug Prescriptions in New York - Hoodline

Apr 29, 2025
pulisher
Apr 29, 2025

Gilead (GILD) Settles Fraud Case with $202 Million Agreement | G - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Gilead Sciences (GILD) Settles DOJ Kickback Allegations for $202M - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Gilead Sciences to Pay $202 Million in Settlement of Illegal Kickbacks Lawsuit - marketscreener.com

Apr 29, 2025
pulisher
Apr 29, 2025

Gilead in $202M settlement with DoJ over kickbacks to doctors - Seeking Alpha

Apr 29, 2025
pulisher
Apr 29, 2025

Gilead Sciences (GILD) Agrees to Pay $202 Million Over Doctor Payments - Bloomberg.com

Apr 29, 2025
pulisher
Apr 29, 2025

Gilead Sciences (NasdaqGS:GILD) Showcases Promising Liver Disease Treatments At EASL Congress - simplywall.st

Apr 29, 2025
pulisher
Apr 29, 2025

Gilead to pay $202 million to settle doctor kickback claims related to HIV drug prescriptions - CNBC

Apr 29, 2025
pulisher
Apr 29, 2025

Gilead to Present Latest Advancements Across Primary Biliary Cho - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Gilead presents new liver disease treatment data at EASL Congress By Investing.com - Investing.com India

Apr 29, 2025
pulisher
Apr 29, 2025

Gilead Sciences: AIDSVu Online Mapping Tool Helps Visualize HIV’s Impact in the United States - Yahoo Finance

Apr 29, 2025
pulisher
Apr 29, 2025

Gilead Sciences (GILD) to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis - StreetInsider

Apr 29, 2025
pulisher
Apr 29, 2025

Biotech Powerhouse: Ex-Gilead CMO Merdad Parsey Strengthens Ardelyx Board with 25-Year Expertise - Stock Titan

Apr 29, 2025
pulisher
Apr 29, 2025

Cancer Immunotherapy Market to Witness Massive Growth by 2032 | - openPR.com

Apr 29, 2025
pulisher
Apr 28, 2025

Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch

Apr 28, 2025
pulisher
Apr 28, 2025

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs - GlobeNewswire Inc.

Apr 28, 2025

Gilead Sciences Inc Stock (GILD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general SNY
$52.32
price down icon 1.63%
drug_manufacturers_general PFE
$22.86
price down icon 0.17%
$274.87
price up icon 1.62%
drug_manufacturers_general MRK
$79.28
price up icon 0.23%
drug_manufacturers_general NVS
$112.02
price up icon 1.35%
Cap:     |  Volume (24h):